Clinical Trial Update: A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin [Phase 3]

View source ↗

Summary

Pfizer's Hospira conducted a Phase 3 long-term safety study of intravenous epoetin alfa in adults with chronic kidney disease requiring hemodialysis. Results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Epoetin alfa (Hospira) (epoetin alfa)

Snippet

Sponsor: Pfizer | Conditions: Chronic Renal Failure Requiring Hemodialysis | Phase 3 | Status: COMPLETED | Results posted: 2018-07-19